85 results
S-3ASR
DAWN
Day One Biopharmaceuticals, Inc.
28 Aug 24
Automatic shelf registration
4:07pm
of patients with pLGG do not yet have access to approved therapies. Tovorafenib received orphan drug designation for the treatment of malignant glioma from … . Arm 2 provided additional safety data from an incremental 60 patients and was initiated to enable access to OJEMDA once Arm 1 had fully accrued
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals, Inc.
30 Jul 24
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
7:35am
$6.1M $2.1M Payer Education Engagement pre & post approval to educate on pLGG enabled early access High Pre-Launch Awareness Awareness pre-launch … and commercial free drug programs. Does not include patients not yet transitioned from EAP. Rapid transition of patients on Early Access Program (EAP
8-K
EX-99.3
DAWN
Day One Biopharmaceuticals, Inc.
30 Jul 24
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
7:35am
enabled early access Payer Education $8.2M in net product revenue in 2Q 2024, for initial 8 weeks of launch following U.S. approval
Coverage Approval … Approved for Coverage, Despite Lower Reported Coverage280% commercial patients70% Medicaid patients
Patient Support Program Supporting Access DEDICATED
8-K
EX-99.1
qqtbamdguj xfbnw
30 Jul 24
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
7:35am
8-K
EX-10.1
1vp2cl5
30 Jul 24
Day One Announces Oversubscribed $175.0 Million Private Placement
7:04am
8-K
EX-99.1
vzzvbfw
30 Jul 24
Day One Announces Oversubscribed $175.0 Million Private Placement
7:04am
8-K
EX-10.2
9slazku5zy 3i
30 Jul 24
Day One Announces Oversubscribed $175.0 Million Private Placement
7:04am
8-K
EX-99.1
7ysu717gr iwrmmxydvx
25 Jul 24
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
6:04am
8-K
EX-99.2
1gnlxwr
18 Jun 24
Entry into a Material Definitive Agreement
8:36am
8-K
EX-99.1
hzd9fl450mfmn
12 Jun 24
Regulation FD Disclosure
8:07am
8-K
EX-99.2
f26n1t4
30 May 24
Day One Announces Sale of Priority Review Voucher for $108 Million
8:35am
8-K
EX-99.2
f9l p7lu5
6 May 24
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.2
a2hq4k3kw wfr
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
EX-99.1
mp3dpjtl5z
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
3dssxj yz1nqjz9
24 Apr 24
Regulation FD Disclosure
8:01am